Notably, treatment with alpelisib not only interfered with PIK3CA-mediated downstream signaling, but also induced a dose-dependent decrease in p110α protein levels in ER+/PIK3CA-mutated breast cancer cell lines [82], suggesting a dual mode of action. Here, PIK3CA is linked to breast carcinoma.